Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate CancerDavid T. Miyamoto, Daniel A. Haber, Richard J. Lee et al.|Cancer Discovery|2012Cited by 271
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Charles S. Cleeland, Karim Fizazi et al.|The Lancet Oncology|2013Cited by 153
Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases.Richard J. Lee, Matthew R. Smith, M. Dror Michaelson et al.|Journal of Clinical Oncology|2012Cited by 2